Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Cash from Financing Activities (2016 - 2026)

Neuroone Medical Technologies filings provide 14 years of Cash from Financing Activities readings, the most recent being $609622.0 for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities rose 148.61% to $609622.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $9.1 million, a 135.68% increase, with the full-year FY2025 number at $8.0 million, up 10.45% from a year prior.
  • Cash from Financing Activities hit $609622.0 in Q1 2026 for Neuroone Medical Technologies, up from $147823.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $8.2 million in Q2 2025 to a low of -$509325.0 in Q4 2024.
  • Median Cash from Financing Activities over the past 5 years was $661961.0 (2023), compared with a mean of $1.6 million.
  • Biggest five-year swings in Cash from Financing Activities: soared 205677.95% in 2023 and later tumbled 142.27% in 2024.
  • Neuroone Medical Technologies' Cash from Financing Activities stood at -$15713.0 in 2022, then soared by 7768.9% to $1.2 million in 2023, then plummeted by 142.27% to -$509325.0 in 2024, then skyrocketed by 129.02% to $147823.0 in 2025, then skyrocketed by 312.4% to $609622.0 in 2026.
  • The last three reported values for Cash from Financing Activities were $609622.0 (Q1 2026), $147823.0 (Q4 2025), and $66978.0 (Q3 2025) per Business Quant data.